{"name":"ObsEva SA","slug":"obseva-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":19637000,"revenueGrowth":-11.5,"grossMargin":0,"rdSpend":10710000,"netIncome":-29879000,"cash":16544000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"Add-back","genericName":"Add-back","slug":"add-back","indication":"Endometriosis (as add-back to GnRH agonist therapy)","status":"phase_3"},{"name":"OBE001","genericName":"OBE001","slug":"obe001","indication":"Preterm labor (delay of preterm birth)","status":"discontinued"},{"name":"Placebo to match Add-back","genericName":"Placebo to match Add-back","slug":"placebo-to-match-add-back","indication":"Matching placebo for add-back therapy","status":"phase_3"},{"name":"Placebo to match OBE2109","genericName":"Placebo to match OBE2109","slug":"placebo-to-match-obe2109","indication":"Other","status":"phase_3"},{"name":"Yselty","genericName":"LINZAGOLIX","slug":"linzagolix","indication":"Uterine fibroids","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"OBE2109","genericName":"OBE2109","slug":"obe2109","indication":"Uterine fibroids (heavy menstrual bleeding)","status":"phase_3"}]}],"pipeline":[{"name":"Add-back","genericName":"Add-back","slug":"add-back","phase":"phase_3","mechanism":"Add-back is a progestin (norethisterone acetate) co-administered with a GnRH agonist to mitigate hypogonadal side effects while maintaining the therapeutic benefits of GnRH suppression.","indications":["Endometriosis (as add-back to GnRH agonist therapy)","Uterine fibroids (as add-back to GnRH agonist therapy)"],"catalyst":""},{"name":"OBE001","genericName":"OBE001","slug":"obe001","phase":"discontinued","mechanism":"OBE001 is an oxytocin receptor antagonist that inhibits uterine contractions by blocking oxytocin signaling in myometrial smooth muscle.","indications":["Preterm labor (delay of preterm birth)","Infertility (embryo transfer support)"],"catalyst":""},{"name":"OBE2109","genericName":"OBE2109","slug":"obe2109","phase":"phase_3","mechanism":"OBE2109 is a selective progesterone receptor modulator that modulates progesterone signaling to treat reproductive and gynecological disorders.","indications":["Uterine fibroids (heavy menstrual bleeding)","Endometriosis-associated pain"],"catalyst":""},{"name":"Placebo to match Add-back","genericName":"Placebo to match Add-back","slug":"placebo-to-match-add-back","phase":"phase_3","mechanism":"This drug is a placebo used to match an add-back therapy.","indications":["Matching placebo for add-back therapy"],"catalyst":""},{"name":"Placebo to match OBE2109","genericName":"Placebo to match OBE2109","slug":"placebo-to-match-obe2109","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance, taste, and administration characteristics of OBE2109 for blinded clinical trial purposes.","indications":[],"catalyst":""},{"name":"Yselty","genericName":"LINZAGOLIX","slug":"linzagolix","phase":"marketed","mechanism":"Gonadotropin-releasing hormone receptor","indications":["Uterine fibroids"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxPV1M3NXRQVDYwUnJSS2F0Nlh5LVRJMFlFQjdOMnc3ODczRXVYbmxVRXZCLVFJMDdCRU01ZHZmRkZjcGY1VjlFQWd2WFBuTFNoZ2ZJRTl0Rk9IcTNmUjZyaDE0ZTBHTFJDRFlYYURnT0xRWUlzWUxwX0VoWmZqMThBUVdVS0NnbHAwN2pjRkV2TVJtVS1GWWI4SF9oYnVlUGUya2NjOHpncXBjN0ZpSjV2dk1ST0VYQWhWNTNIdkdLYmU3OEk3UGR3WjNyaFk4aWtfaHF5SUtSZHFJRUdYMW9kMVl5MUVrVU52RVFlRUdQOVE?oc=5","date":"2025-01-29","type":"trial","source":"PR Newswire","summary":"Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Endometriosis Clinical Trial Pipeline Gains Momentum as 15+ Key Companies at the Forefront | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxONW9LNmpFdGdSRHNGQ2h1Q0lpQ3hwVU5uUVRRWm02YVZ4M19iYjhwZ2t3WThmTnBWY3hTUjFrc1B4UE1rUFlnTWhqVVh3MW9GX0QzYjdHNE1hZUVsWUlMbGtnT3FUWENVWTRlU0NobVptb3ExN0R4WE9ycDU3eWR4VGVxZVJKY0lka0ZBX0M1dmI?oc=5","date":"2024-09-16","type":"pipeline","source":"grandviewresearch.com","summary":"Canada Endometriosis Treatment Market Size & Outlook, 2033 - grandviewresearch.com","headline":"Canada Endometriosis Treatment Market Size & Outlook, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOWU11NExhZkYtczBjdGs1eXhtOV8ycEdxRU1LUGNad0JFajlvYlVzUm9yMDd1OGRVR1BnVWVZSm5VR1B5cDROZnVrS1hoRW9wanpzZlptNzlSRHFZeFhxRkh4ZHhXNFNnNkF3NnNSblR0eUdYLVI3THBTRjQ0SG42V0M4V281VnVUNktUZTdYMU5DdEVUTDlCdQ?oc=5","date":"2024-09-03","type":"pipeline","source":"grandviewresearch.com","summary":"South Africa Endometriosis Treatment Market Size & Outlook, 2033 - grandviewresearch.com","headline":"South Africa Endometriosis Treatment Market Size & Outlook, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTEpqWkZpaUR2WlJ6TnBCem4wLTZ5eFVDS0lvYi1wT21LU0I3cVhUSEV1cmo0ckNOU0RNWThyOHhNQWNqalBPQm9EclpxMjZoQ2drbTNBVm9CWXZCMVdpQUthbl85SlA0T0hEVDdFVG5nS2IxZWZSTWZMZXdIRGlCWGxiR1JQR0h0RFhyXzFyOXpZYVBPc3pza0Z3azk?oc=5","date":"2024-02-28","type":"pipeline","source":"Fierce Biotech","summary":"ObsEva winds down and lays off all staff as money, options run out - Fierce Biotech","headline":"ObsEva winds down and lays off all staff as money, options run out","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPZ1I0MW1aQ3NUWU5JZExNVkNvYU5yU2liZ05hOWNQbjF3U2Z0cUFsLS0yQU5SbVdpamxCSG4xVmhTcjJ0S2ZVMnJKWmlBUVh2Um1lWlZiNmpuelloVWR5LTBob3p0ZFVBaHpiMFYweWxNMFg0R3J3U2s4Nl9SWm5rOEFPV1hEWU5pQklOTmdR?oc=5","date":"2023-09-15","type":"pipeline","source":"citybiz","summary":"Deep Genomics Appoints Brian O’Callaghan as CEO - citybiz","headline":"Deep Genomics Appoints Brian O’Callaghan as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQTDM1LTVDNzB0YU1xUldodURyUjQ3a0Qxc0pXWTJ1M1RZdFBRSW9SN1AxZlJsWEZoSXFzTGREZ3VvR3ZZTUNBdi1RX3pXZlJLZkNQb3ViaXhCb19xZElhRzJJcjhDbTB0OEZzaWlSMHdFd0dON3NXdHJIT3JTTWFiajNJN2RDQWJVcWI3S25Jb0xBQ2c0eDl4OThMVWRIR1RoNmswNEZXTjREUGJfaGJIV1hpdmFJUVVFZ3ZB?oc=5","date":"2023-05-29","type":"regulatory","source":"Citeline News & Insights","summary":"Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else - Citeline News & Insights","headline":"Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else - Citeline News & Insights","sentiment":"positive"},{"date":"2023-04-17","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SC 13D","headline":"SC 13D Filing","sentiment":"neutral"},{"date":"2023-04-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNMm1jci1aRF9pXzVma2ZzZGdOVlpWUFZlWXJjXzZzY3V2LUR2WXRfeHROeEdFNWxhMkVNbWp0QUx2d3o0bmZRMml2ajRxZHNienhmV1dURzJpc2tKTmcyOXJZQ2o3RnFEQ0h3OVlmVThiVEtCMWVKV2NoTzVqRGdzRkQzY1oweDZGcUI0ZWFXSQ?oc=5","date":"2022-12-14","type":"trial","source":"AlphaSense","summary":"300+ transcripts from JPM's 39th Annual Healthcare Conference - AlphaSense","headline":"300+ transcripts from JPM's 39th Annual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxORm85a0F4U2RDb0pQc2FRU0FLY0Q2V3dkTGE2dDdPZkFyaldwMzM0ZU5hTkZQNVZyd3JITDBlVGluSXBzWXNEcFJwNU9OQlpSV2tXTC05VE1RNXlrUXVxQmdSUWtJNlRzUDhWZVJSZDhiOS1pVHY1WXI5eW5ZQTNhSEV1MlZUR21BN2MwcE56YWZIb2w0NmxDd1lEUE9oSGVMUjJGUkZ2N1U1MHB5REg3ZkpXRlUtc3FISzBFNDVSSTgzdEZxVFJmei1SUXJFaUxJa3loTWhiNnJ6V0ZDQnlEcWxiQkFJSHJZd3pXcTFaazFEWWRsYXpuUXpTXzF6cWFjT2E5UWlMNy1MZDZtb2gzUl9pYVk2NTIyWWtKSkY2U3pTc2VrRnJ0WENoT1VLemhCeVRJWF94Z2dveWwz?oc=5","date":"2022-06-17","type":"pipeline","source":"GlobeNewswire","summary":"ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids - GlobeNewswire","headline":"ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPVEtFaEFzZXA2cGtQNFdZZEdnREo4S1FOVFhEdzZUUlZLUDN2b3JNNjFCc1J1Vk1URlZNUEloVE4tbVNSc1dsSGlxbmhXbWdkSkRhT0dPWEFYS3hqb1hHbm9QWnB4Q2tSRlAyV3B1RV9TVVdOS3NWVjh4VFI5X3J5eFRPbVpqZUFCVlFseE5hcmlKMHQ1Y3FmYVBfNC1RbzIwQjNTTnJPZkR1WUlfYlp4c0pMa0xkY2hGOEw5UWt3LWstM0tVTDdINHY5N2ZBN2dNNWxyYUxtUktHeXBjSmd5NldQRHoxbnZONWNLTVZoSGVaVk9kXzRF?oc=5","date":"2022-02-10","type":"pipeline","source":"GlobeNewswire","summary":"ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix - GlobeNewswire","headline":"ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNNWVuSnVBcjVXMTdxYW1vQ2dlQm4ydGVoVjU1QXVsLXptRDhpN0pYdHFDd2dKazI1OEx5SklZdjlEb3dkYzNJMnFZRXJfWHNWaklIQnVzRGdOYWRXZnpJVFl1LTZ5OE1LTFRTV19XUGFIcjdHZTI1Ym5rNHIwWnYwQ3FLdw?oc=5","date":"2017-12-18","type":"pipeline","source":"BioPharma Dive","summary":"Biotech IPOs show no signs of slowing down in 2018 - BioPharma Dive","headline":"Biotech IPOs show no signs of slowing down in 2018","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":4,"discontinued":1,"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":19637000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":19637000,"period":"2022-12-31"},{"value":22200000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":10710000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-29879000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":16544000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}